carbon monoxide has been researched along with Hematologic Malignancies in 7 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)." | 3.73 | Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006) |
| " In three patients the pulmonary disorder seems to have been caused by a cell-mediated immunological side effect in the form of interstitial pneumonitis." | 1.32 | Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. ( Anderson, P; Höglund, M; Rödjer, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coffey, DG | 1 |
| Pollyea, DA | 1 |
| Myint, H | 1 |
| Smith, C | 1 |
| Gutman, JA | 1 |
| Au, BK | 1 |
| Gooley, TA | 1 |
| Armand, P | 1 |
| Fang, M | 1 |
| Madtes, DK | 1 |
| Sorror, ML | 1 |
| Boeckh, MJ | 1 |
| Gibson, CJ | 1 |
| Deeg, HJ | 1 |
| Storb, R | 1 |
| Appelbaum, FR | 1 |
| Chien, JW | 2 |
| Martin, PJ | 1 |
| Li Volti, G | 1 |
| Tibullo, D | 1 |
| Vanella, L | 1 |
| Giallongo, C | 1 |
| Di Raimondo, F | 1 |
| Forte, S | 1 |
| Di Rosa, M | 1 |
| Signorelli, SS | 1 |
| Barbagallo, I | 1 |
| Sullivan, KM | 1 |
| Anderson, P | 1 |
| Höglund, M | 1 |
| Rödjer, S | 1 |
| van der Lee, I | 1 |
| Zanen, P | 1 |
| van den Bosch, JM | 1 |
| Lammers, JW | 1 |
| Savani, BN | 1 |
| Montero, A | 1 |
| Srinivasan, R | 1 |
| Singh, A | 1 |
| Shenoy, A | 1 |
| Mielke, S | 1 |
| Rezvani, K | 1 |
| Karimpour, S | 1 |
| Childs, R | 1 |
| Barrett, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078] | Phase 2 | 25 participants (Actual) | Interventional | 2011-01-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 3 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 7 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 9 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 1 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
1 review available for carbon monoxide and Hematologic Malignancies
| Article | Year |
|---|---|
The Heme Oxygenase System in Hematological Malignancies.
Topics: Animals; Antineoplastic Agents; Biliverdine; Carbon Monoxide; Epigenesis, Genetic; Hematologic Neopl | 2017 |
1 trial available for carbon monoxide and Hematologic Malignancies
| Article | Year |
|---|---|
Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.
Topics: Adolescent; Adult; Alanine Transaminase; Allografts; Carbon Monoxide; Child; Creatinine; Disease-Fre | 2015 |
5 other studies available for carbon monoxide and Hematologic Malignancies
| Article | Year |
|---|---|
Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
Topics: Adult; Aged; Carbon Monoxide; Comorbidity; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Tr | 2013 |
Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?
Topics: Adult; Carbon Monoxide; Diffusion; Female; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic | 2009 |
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
Topics: Adult; Aged; Autoimmunity; Carbon Monoxide; Female; Hematologic Neoplasms; Humans; Immunity, Cellula | 2003 |
Pattern of diffusion disturbance related to clinical diagnosis: The K(CO) has no diagnostic value next to the DL(CO).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Blood-Air Barrier; Carbon Monoxide; Diffusio | 2006 |
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female | 2006 |